​

Werewolf Therapeutics (HOWL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Werewolf Therapeutics Revenue Highlights

Latest Revenue (Y)

$1.89M

Latest Revenue (Q)

$1.14M

Main Segment (Y)

Reportable Segment

Werewolf Therapeutics Revenue by Period

Werewolf Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$1.89M-90.55%
2023-12-31$19.94M21.60%
2022-12-31$16.40M100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Werewolf Therapeutics generated $1.89M in revenue during NA 2024, up -90.55% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Werewolf Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$1.14M54.04%
2024-03-31$742.00K-50.57%
2023-12-31$1.50M-74.55%
2023-09-30$5.90M-27.03%
2023-06-30$8.08M81.03%
2023-03-31$4.46M-38.71%
2022-12-31$7.28M46.54%
2022-09-30$4.97M19.82%
2022-06-30$4.15M100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Werewolf Therapeutics generated $1.14M in revenue during Q2 2024, up 54.04% compared to the previous quarter, and up 25.60% compared to the same period a year ago.

Werewolf Therapeutics Revenue Breakdown

Werewolf Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Reportable Segment$1.89M

Werewolf Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).

Werewolf Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
GLUEMonte Rosa Therapeutics$75.62M$4.70M
STOKStoke Therapeutics$36.55M$4.89M
CCCCC4 Therapeutics$20.76M-
MOLNMolecular Partners$7.04M$2.74M
HOWLWerewolf Therapeutics$1.89M$1.14M
MNOVMediciNova$1.00M-
IKNAIkena Oncology--
ANEBAnebulo Pharmaceuticals--
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
EWTXEdgewise Therapeutics--
ACETAdicet Bio--
THRDThird Harmonic Bio--
PASGPassage Bio--
ACRVAcrivon Therapeutics--
CELCCelcuity--
VORVor Biopharma--
CSBRChampions Oncology--

HOWL Revenue FAQ

What is Werewolf Therapeutics’s yearly revenue?

Werewolf Therapeutics's yearly revenue for 2024 was $1.88M, representing a decrease of -90.55% compared to 2023. The company's yearly revenue for 2023 was $19.94M, representing an increase of 21.60% compared to 2022. HOWL's yearly revenue for 2022 was $16.4M, representing an increase of 100.00% compared to 2021.

What is Werewolf Therapeutics’s quarterly revenue?

Werewolf Therapeutics's quarterly revenue for Q2 2024 was $1.14M, a 54.04% increase from the previous quarter (Q1 2024), and a -85.86% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $742K, a -50.57% decrease from the previous quarter (Q4 2023), and a -83.38% decrease year-over-year (Q1 2023). HOWL's quarterly revenue for Q4 2023 was $1.5M, a -74.55% decrease from the previous quarter (Q3 2023), and a -79.39% decrease year-over-year (Q4 2022).

What is Werewolf Therapeutics’s revenue growth rate?

Werewolf Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -88.51%, and for the last 5 years (2020-2024) was 0%.

What are Werewolf Therapeutics’s revenue streams?

Werewolf Therapeutics's revenue streams in c 24 are Reportable Segment

What is Werewolf Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Werewolf Therapeutics was Reportable Segment. This segment made a revenue of $1.88M, representing 100.00% of the company's total revenue.